AU2339299A - Immune effector cell hybrids - Google Patents

Immune effector cell hybrids Download PDF

Info

Publication number
AU2339299A
AU2339299A AU23392/99A AU2339299A AU2339299A AU 2339299 A AU2339299 A AU 2339299A AU 23392/99 A AU23392/99 A AU 23392/99A AU 2339299 A AU2339299 A AU 2339299A AU 2339299 A AU2339299 A AU 2339299A
Authority
AU
Australia
Prior art keywords
cells
antigen
immune effector
population
effector cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU23392/99A
Other languages
English (en)
Inventor
Jianlin Gong
Donald Kufe
Charles A. Nicolette
Bruce L. Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Genzyme Corp
Original Assignee
Dana Farber Cancer Institute Inc
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Genzyme Corp filed Critical Dana Farber Cancer Institute Inc
Publication of AU2339299A publication Critical patent/AU2339299A/en
Assigned to GENZYME CORPORATION, DANA-FARBER CANCER INSTITUTE, INC. reassignment GENZYME CORPORATION Alteration of Name(s) of Applicant(s) under S113 Assignors: GENZYME CORPORATION
Priority to AU2003271378A priority Critical patent/AU2003271378B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU23392/99A 1998-01-26 1999-01-25 Immune effector cell hybrids Abandoned AU2339299A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003271378A AU2003271378B2 (en) 1998-01-26 2003-12-24 Immune effector cell hybrids

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8835798P 1998-01-26 1998-01-26
US60088357 1998-01-26
US8004198P 1998-03-31 1998-03-31
US60080041 1998-03-31
PCT/US1999/001464 WO1999037313A1 (en) 1998-01-26 1999-01-25 Immune effector cell hybrids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003271378A Division AU2003271378B2 (en) 1998-01-26 2003-12-24 Immune effector cell hybrids

Publications (1)

Publication Number Publication Date
AU2339299A true AU2339299A (en) 1999-08-09

Family

ID=26762993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23392/99A Abandoned AU2339299A (en) 1998-01-26 1999-01-25 Immune effector cell hybrids

Country Status (5)

Country Link
EP (1) EP1071436A4 (enExample)
JP (2) JP2002500872A (enExample)
AU (1) AU2339299A (enExample)
CA (1) CA2318987A1 (enExample)
WO (1) WO1999037313A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
EP1168924A4 (en) * 1999-03-31 2002-09-04 Univ Pittsburgh DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL
DE60226853D1 (de) * 2001-02-20 2008-07-10 Ortho Mcneil Pharm Inc Zelltherapieverfahren für die behandlung von tumoren
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
FR2828934B1 (fr) * 2001-08-27 2004-08-13 Inst Nat Sante Rech Med Test de l'immunite cellulaire par des peptides fixes sur support solide
AU2003275767A1 (en) * 2002-11-07 2004-06-07 Johnson & Johnson Research Pty Limited A means of producing and utilising a population of disease specific cytotoxic T-lymphocytes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
DE69839215T2 (de) * 1997-04-15 2009-03-19 Dana-Farber Cancer Institute, Inc., Boston Dendritische zellhybride

Also Published As

Publication number Publication date
EP1071436A4 (en) 2003-08-27
CA2318987A1 (en) 1999-07-29
EP1071436A1 (en) 2001-01-31
JP2002500872A (ja) 2002-01-15
WO1999037313A1 (en) 1999-07-29
JP2009195235A (ja) 2009-09-03

Similar Documents

Publication Publication Date Title
US20020164346A1 (en) Altered peptide ligands
US20020018766A1 (en) Genes differentially expressed in cancer cells to design cancer vaccines
US7601342B2 (en) Cell fusions and methods of making and using the same
US20020041868A1 (en) Cell fusions and methods of making and using the same
JP2009195235A (ja) 免疫エフェクター細胞ハイブリッド
US20020006397A1 (en) In VIVO loading of MHC
AU3102299A (en) Compositions and methods for gene-based vaccines to provoke T cell responses
AU3102999A (en) Induction of immunity against tumor self-antigens
AU2003271378B2 (en) Immune effector cell hybrids
AU2007231612B2 (en) Immune effector cell hybrids
EP1063891A2 (en) Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
AU2007201829A1 (en) Immune effector cell hybrids
AU761256B2 (en) Antigen-specific cells, methods of generating these cells and uses thereof
AU759765B2 (en) Compositions and methods for antigen-specific vaccination
US20020065241A1 (en) Antigenic peptide concatomers
AU1102100A (en) Peptides related to an igf-ii-r epitope, polynucleotides encoding the peptides, and their use in immunomodulation
US7014848B1 (en) Enhanced anti-tumor immunity
AU2014268156A1 (en) A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND INVENTORS TO INCLUDE: DONALD KUFE AND JIANLIN GONG

PC1 Assignment before grant (sect. 113)

Owner name: GENZYME CORPORATION, DANA-FARBER CANCER INSTITUTE

Free format text: THE FORMER OWNER WAS: GENZYME CORPORATION

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted